4 products found
Qualigen Therapeutics, Inc. Products
-
Therapeutics Pipeline
-
Model QN-302 - G4 Binders As Potent Selective Transcription Inhibitors
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Developed by Dr. Stephen Neidle and his group at UCL, the G4 binding concept is derived from 30+ years in nucleic acid research, including ...
-
Model QN-247 - Aptamer-Based investigational Drug
QN-247, formerly referred to as ALAN (Aptamer Linked Anti Nucleolin), is an aptamer-based investigational drug candidate currently under development and evaluation with the potential to treat a variety of different cancer types, including liquid and solid tumors. A key component of this drug candidate, the QN-165 aptamer, has been tested in over 100 cancer patients and is well tolerated with no evidence of severe side effects; with at least 7 patients ...
-
Model RAS-F - RAS Protein Inhibitors as Treatments for Advanced Solid Tumors
Our RAS-F portfolio includes lead and back-up small molecules that suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS, and NRAS effector pathways. This potentially enables a differentiated, RAS-targeted strategy for inhibiting the MAPK, PI3K, and TOR pathways that are implicated in cancer cell proliferation, survival, and differentiation (see figure). RAS itself acts as a “hub” that activates multiple effector ...
-
Model STARS - Investigational Therapeutic Device Product
Since its inception, the Qualigen’s initial R&D focus has been on its FastPack diagnostic system and related core technologies. These same technologies are now the basis for the Company’s expansion into therapeutic applications for the treatment of cancer and infectious disease. Qualigen’s Selective Target Antigen Removal System (STARS), is an investigational therapeutic device product currently under development and evaluation that ...